Accreditation
Target Audience
The target audience for this activity is oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists charged with the care of patients with breast cancer.
Learning Objectives
- Evaluate clinical efficacy and safety data of currently approved and emerging agents for HR+/HER2– breast cancer and their impact on current treatment paradigms
- Assess currently available and potential future treatment approaches to the care of patients with triple-negative breast cancer
- Discuss the unique treatment approaches to treating HER2+ breast cancer and strategies to optimize patient outcomes
- Compare and contrast multidisciplinary perspectives for the care of patients with breast cancer, including the role of the medical oncologist, surgeon, and radiation oncologist
Accreditation
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
|
Faculty
|
Conflicts of Interest
|
|---|---|
|
Sarah Hurvitz, MD, FACP
|
Researcher: Arvinas, Inc., AstraZeneca, Bayer Corporation, Celcuity Inc., Daiichi Sankyo, Inc., Dantari G1 Therapeutics, Inc., Genentech, Inc., F. Hoffmann La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline, Greenwich Life Sciences, Inc., Immunomedics, Inc., Lilly, Macrogenics, Inc., Novartis Pharmaceuticals Corporation, Orum, Pfizer, Radius Health, Inc., Sanof, Seagan Inc., Zymeworks, Inc., Jazz/Zymeworks Inc., Stemline Menarini Consultant/Advisor/Speaker: Briacell, Beigene, BridgeBio, Blueprint, Embiosys, Luminate, Gilead Breast Cancer Council, Daiichi Sankyo, Novartis, Roche Global, BMS, Jazz, Menarini Stemline, Mersana, Arvinas/Pfizer Data Safety Board: Quantum Leap InClin/Atossa trial
|
|
Claudine Isaacs, MD
|
Consultant/Advisor/Speaker: Arvinas, AstraZeneca, Genentech, Novartis, Pfizer, Gilead, Merck, Seattle Genetics Royalties/Patent Beneficiary: Wolters Kluwer, McGraw Hill Institutional Support: Tesaro/GSK, Seattle Genetics, Pfizer, BMS, Genentech, Novartis
|
|
Reshma Jagsi, MD, DPhil
|
Advisory Panel: Blue Cross Blue Shield
|
|
Kevin Kalinsky, MD, MS, FASCO
|
Consultant/Advisor/Speaker: Genentech/Roche, Gilead, Seattle Genetics, AstraZeneca, Daiichi Sankyo, Puma Biotechnology, Mersana, Menarini Silicon Biosystems, Myovant Sciences, Merck, Eli Lilly, Pfizer, Novartis, ProteinQure, bioTheranostics, Regor, Relay Therapeutics Employee (Spouse): EQRX (prior), ADC Therapeutics
|
|
Tari King, MD, FACS, FSSO, FASCO
|
Consultant/Advisor/Speaker: Veracyte, GE Healthcare, Exact Sciences
|
|
Sarah McLaughlin, MD
|
Has no relevant financial relationships
|
|
Joyce O’Shaughnessy, MD
|
Consultant/Advisor/Speaker: AADI Bioscience, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, BioNTech, BMS, Daiichi Sankyo, Duality, Eisai, Eli Lilly, Ellipses, Exact Science, G1 Therapeutics, Genentech, Gilead Sciences, Guardant Health, Hibercell, Jazz Pharmaceuticals, Johnson & Johnson, Menarini Stemline, Merck, Mersana, Natera, Novartis, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, RayzeBio, Roche, Sanofi, Seagen, Stemline Therapeutics, Summitt Therapeutics, TerSera Therapeutics
|
|
Mylin Torres, MD
|
Educational Lectures: Varian
|
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
To receive CE credit, learners must follow these steps:
- Link for activity evaluation coming soon
- Complete the activity evaluation
- Upon completion of all evaluation questions, your credit will be made available for download immediately.